Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Daniel Wiseman

Daniel Wiseman

The Christie NHS Foundation Trust
Updates in CMML: consensus guidelines, promising therapeutic approaches, & more 22:21
Updates in CMML: consensus guidelines, promising therapeutic approaches, & more
Daniel Wiseman • 13 Mar 2025
The most promising therapeutic approaches currently being investigated for CMML 5:37
The most promising therapeutic approaches currently being investigated for CMML
Daniel Wiseman • 13 Mar 2025
The prognostic and therapeutic implications of TP53 expression in CMML 2:50
The prognostic and therapeutic implications of TP53 expression in CMML
Daniel Wiseman • 13 Mar 2025
Studying blast phase CMML uncovers two distinct subgroups and significant heterogeneity 4:06
Studying blast phase CMML uncovers two distinct subgroups and significant heterogeneity
Daniel Wiseman • 13 Mar 2025
Updates in the management of CMML: a case-based presentation 6:50
Updates in the management of CMML: a case-based presentation
Daniel Wiseman • 13 Mar 2025
The management of CMML in the UK 2:53
The management of CMML in the UK
Daniel Wiseman • 13 Mar 2025
Day 1 highlights: imetelstat in MF, challenges with MPN/MDS overlap syndromes & future outlooks
Claire Harrison et al. • 19 Jul 2024
Aiming to advance the diagnosis and treatment of CMML and BPDCN
Daniel Wiseman et al. • 18 Jul 2024
Managing sAML from MDS 2:14
Managing sAML from MDS
Daniel Wiseman • 4 Apr 2022
Emerging treatment strategies for CMML 3:20
Emerging treatment strategies for CMML
Daniel Wiseman • 4 Apr 2022
Genetic predispositions to MDS 1:03
Genetic predispositions to MDS
Daniel Wiseman • 4 Apr 2022
Diagnosis and management of CMML 3:05
Diagnosis and management of CMML
Daniel Wiseman • 4 Apr 2022
The content of VJHemOnc is intended for healthcare professionals